Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:CALT NASDAQ:OGI NASDAQ:PRVB NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$19.81+2.1%$22.79$12.21▼$39.50$543.14M-0.19489,778 shs718,387 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AOGIOrganigram Global$1.77+0.6%$1.55$0.85▼$1.95$236.44M1.49689,624 shs506,529 shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsRIGLRigel Pharmaceuticals$34.22-2.2%$31.16$13.37▼$43.72$627.45M1.27696,312 shs447,427 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-3.77%-12.34%-3.67%-17.06%-49.90%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%-0.77%OGIOrganigram Global+2.92%+7.98%+23.08%+33.33%-6.88%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%RIGLRigel Pharmaceuticals-6.22%-2.64%-11.47%+80.68%+154.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$19.81+2.1%$22.79$12.21▼$39.50$543.14M-0.19489,778 shs718,387 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AOGIOrganigram Global$1.77+0.6%$1.55$0.85▼$1.95$236.44M1.49689,624 shs506,529 shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsRIGLRigel Pharmaceuticals$34.22-2.2%$31.16$13.37▼$43.72$627.45M1.27696,312 shs447,427 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-3.77%-12.34%-3.67%-17.06%-49.90%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%-0.77%OGIOrganigram Global+2.92%+7.98%+23.08%+33.33%-6.88%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%RIGLRigel Pharmaceuticals-6.22%-2.64%-11.47%+80.68%+154.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$46.13132.84% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AOGIOrganigram Global 0.00N/AN/AN/APRVBProvention Bio 0.00N/AN/AN/ARIGLRigel Pharmaceuticals 2.40Hold$38.2011.63% UpsideCurrent Analyst Ratings BreakdownLatest OGI, ANAB, PRVB, RIGL, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$45.008/12/2025ANABAnaptysBioUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $20.008/7/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $45.008/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $32.007/24/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $80.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M6.08N/AN/A$2.33 per share8.50CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74OGIOrganigram Global$117.47M2.02N/AN/A$2.07 per share0.86PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84RIGLRigel Pharmaceuticals$179.28M3.42$1.06 per share32.42$0.19 per share180.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AOGIOrganigram Global-$33.39M$0.0535.41N/AN/A2.86%-8.19%-5.79%N/APRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ARIGLRigel Pharmaceuticals$17.49M$5.416.3332.59N/A36.51%438.89%57.03%11/6/2025 (Estimated)Latest OGI, ANAB, PRVB, RIGL, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025OGIOrganigram Global-$0.01-$0.03-$0.02-$0.03$68.04 million$50.49 million8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22CALTCalliditas Therapeutics AB (publ)9.442.692.59OGIOrganigram GlobalN/A2.591.42PRVBProvention Bio0.191.931.92RIGLRigel Pharmaceuticals0.462.021.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACALTCalliditas Therapeutics AB (publ)2.83%OGIOrganigram Global34.63%PRVBProvention Bio37.39%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%CALTCalliditas Therapeutics AB (publ)2.20%OGIOrganigram Global0.09%PRVBProvention Bio13.10%RIGLRigel Pharmaceuticals9.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableOGIOrganigram Global860134.34 million133.93 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableRIGLRigel Pharmaceuticals16017.94 million16.24 millionOptionableOGI, ANAB, PRVB, RIGL, and CALT HeadlinesRecent News About These CompaniesRigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Down 4.9% - Should You Sell?September 17 at 4:40 PM | marketbeat.comWhat Does Wall Street Think About Rigel Pharmaceuticals (RIGL)?September 17 at 3:31 PM | insidermonkey.comAcadian Asset Management LLC Grows Stock Position in Rigel Pharmaceuticals, Inc. $RIGLSeptember 15 at 4:37 AM | marketbeat.comDynamic Technology Lab Private Ltd Acquires Shares of 27,117 Rigel Pharmaceuticals, Inc. $RIGLSeptember 13, 2025 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Shares Down 6.1% - Here's What HappenedSeptember 11, 2025 | marketbeat.comCan Tavalisse Drive Rigel's Growth Through the Rest of 2025?September 11, 2025 | zacks.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Drop in Short InterestSeptember 11, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Grows Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 11, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Recommendation of "Hold" by AnalystsSeptember 11, 2025 | marketbeat.comWhat Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comA Look At The Intrinsic Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)September 9, 2025 | uk.finance.yahoo.comTrexquant Investment LP Lowers Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 9, 2025 | marketbeat.comDo Options Traders Know Something About RIGL Stock We Don't?September 6, 2025 | msn.comRafferty Asset Management LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGLSeptember 5, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 11,070 Shares of Rigel Pharmaceuticals, Inc. $RIGLSeptember 3, 2025 | marketbeat.comArmistice Capital LLC Has $27.27 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 2, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. $RIGL Shares Bought by Wellington Management Group LLPSeptember 2, 2025 | marketbeat.com115,218 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Nuveen LLCSeptember 1, 2025 | marketbeat.comInvesco Ltd. Purchases Shares of 134,072 Rigel Pharmaceuticals, Inc. $RIGLSeptember 1, 2025 | marketbeat.comVanguard Group Inc. Has $18.50 Million Stake in Rigel Pharmaceuticals, Inc. $RIGLSeptember 1, 2025 | marketbeat.comRigel to Participate in Upcoming September Investor ConferencesAugust 26, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tBy Thomas Hughes | September 8, 2025OGI, ANAB, PRVB, RIGL, and CALT Company DescriptionsAnaptysBio NASDAQ:ANAB$19.81 +0.41 (+2.11%) Closing price 04:00 PM EasternExtended Trading$19.80 -0.01 (-0.05%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 09/16/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Organigram Global NASDAQ:OGI$1.77 +0.01 (+0.57%) Closing price 04:00 PM EasternExtended Trading$1.77 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Provention Bio NASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Rigel Pharmaceuticals NASDAQ:RIGL$34.22 -0.76 (-2.17%) Closing price 04:00 PM EasternExtended Trading$34.96 +0.74 (+2.16%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
